相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Vector Science & Therapeutics filed its first quarterly financial statements as a public company following its April 2026 reverse takeover with OpenSesame Acquisition Corp. - The company expects first revenue from its cGMP peptide manufacturing vertical in August 2026, with production capacity scaling to approximately 800,000 vials per month by early fall. - VectorMist, a perioperative pain management technology for laparoscopic surgery, is advancing toward FDA 510(k) submission with potential revenue before year-end 2026. - The global peptide market is valued at approximately US$141 billion and projected to reach US$295 billion by 2033, with current demand outstripping licensed supply.
- Samsung Biologics announced a $1.8 billion all-cash acquisition of Swiss CDMO PolyPeptide Group, the largest pharma M&A in South Korean history. - The deal expands Samsung's portfolio beyond antibodies, mRNA, and ADCs into peptides, including GLP-1 therapies for obesity and diabetes. - PolyPeptide Group brings six global sites, approximately 1,500 staff, and over 1,000 peptide development projects to Samsung's operations. - The global peptide CDMO market is projected to grow from $5.52 billion to $29.14 billion by 2035, driven by surging obesity treatment demand.
- The US Department of Defense added WuXi AppTec to its Section 1260H list of "Chinese military companies," triggering provisions under the Biosecure Act. - WuXi AppTec, which generates three-quarters of its revenue from the US, has denied any association with the Chinese government and plans to appeal the designation. - Under the Biosecure Act, US companies with preexisting contracts have a 5-year transition period starting in 2028, but analysts warn supply chain disruptions could begin much earlier. - Analysts suggest European and North American competitors such as Bachem, PolyPeptide Group, Charles River Laboratories, and Evotec could benefit from the shift away from WuXi AppTec.
- Alzinova AB has successfully released the drug substance for its ALZ-101 vaccine candidate, enabling final drug product manufacturing for an upcoming Phase 2 clinical trial in early Alzheimer's disease scheduled to begin in the second half of 2025. - The Phase 1b clinical trial results for ALZ-101 demonstrated a favorable safety profile, strong immune response against toxic amyloid-beta oligomers, and promising early signals of disease stabilization in patients with early Alzheimer's disease. - Produced by Polypeptide Laboratories under GMP standards, the partnership will continue to optimize manufacturing processes for late-stage clinical trials, focusing on enhancing production efficiency and scalability for potential commercialization.
